"Menorrhagia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Excessive uterine bleeding during MENSTRUATION.
| Descriptor ID |
D008595
|
| MeSH Number(s) |
C13.351.500.852.691.449 C23.550.568.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Menorrhagia".
Below are MeSH descriptors whose meaning is more specific than "Menorrhagia".
This graph shows the total number of publications written about "Menorrhagia" by people in this website by year, and whether "Menorrhagia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 2 | 1 | 3 |
| 2022 | 5 | 0 | 5 |
| 2023 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Menorrhagia" by people in Profiles.
-
A plain language summary of the long-term relugolix combination therapy study for uterine fibroids. J Comp Eff Res. 2023 08; 12(8):e230069.
-
A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies. Pain Manag. 2023 Apr; 13(4):205-211.
-
Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set. BJOG. 2023 10; 130(11):1337-1345.
-
Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023 03; 228(3):320.e1-320.e11.
-
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 Dec 01; 140(6):920-930.
-
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022 09 17; 400(10356):896-907.
-
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
-
An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
-
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
-
Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.